Abstract
BackgroundCertolizumab pegol (CZP) administered every 4 weeks (Q4W) for RA was shown to have an acceptable safety profile when given as monotherapy in FAST4WARD (NCT00548834) or with MTX in the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have